The pharmacological properties and therapeutic use of apomorphine

Molecules

Volumn 17, Issue 5, 2012, Pages 5289-5309

  Ribaric, Samo ^a,b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Alzheimer's disease; Apomorphine; Dopamine agonist; Erectile dysfunction; Parkinson's disease

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; APOMORPHINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; SEROTONIN RECEPTOR;

ADDICTION; ALZHEIMER DISEASE; ANIMAL; DOG; ERECTILE DYSFUNCTION; FEMALE; HUMAN; MALE; METABOLISM; PARKINSON DISEASE; REVIEW;

ALZHEIMER DISEASE; ANIMALS; APOMORPHINE; DOGS; DOPAMINE AGONISTS; ERECTILE DYSFUNCTION; FEMALE; HUMANS; MALE; PARKINSON DISEASE; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SUBSTANCE-RELATED DISORDERS;

EID: 84861487798     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17055289     Document Type: Review

References (102)

1. LeWitt, P.A. Subcutaneously administered apomorphine: Pharmacokinetics and metabolism. Neurology 2004, 62 (Suppl. 4), S8-S11.
2. Muguet, D.; Broussolle, E.; Chazot, G. Apomorphine in patients with Parkinson's disease. Biomed. Pharmacother. 1995, 49, 197-209.
3. Millan, M.J.; Maiofiss, L.; Cussac, D.; Audinot, V.; Boutin, J.A.; Newman-Tancredi, A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther. 2002, 303, 791-804.
4. Nutt, J.G.; Gancher, S.T.; Woodward, W.R. Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 1988, 38, 1553-1557.
5. Gassen, M.; Glinka, Y.; Pinchasi, B.; Youdim, M.B. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 1996, 308, 219-225.
6. Grunblatt, E.; Mandel, S.; Gassen, M.; Youdim, M.B. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. J. Neural. Transm. Suppl. 1999, 55, 57-70.
7. Li, A.; Guo, H.; Luo, X.; Sheng, J.; Yang, S.; Yin, Y.; Zhou, J. Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons. FASEB J. 2006, 20, 1263-1265.
8. Gancher, S.T.; Woodward, W.R.; Boucher, B.; Nutt, J.G. Peripheral pharmacokinetics of apomorphine in humans. Ann. Neurol. 1989, 26, 232-238.
9. Apomorphine-Compound Summary (CID 6005) Apomorphine PubChem. Available online: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6005 (accessed on 28 February 2012
10. Deleu, D.; Hanssens, Y.; Northway, M.G. Subcutaneous apomorphine: An evidence-based review of its use in Parkinson's disease. Drugs Aging 2004, 21, 687-709.
11. Holford, N.H.; Sheiner, L.B. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 1981, 6, 429-453.
12. Neef, C.; van Laar, T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin. Pharmacokinet. 1999, 37, 257-271.
13. Neumeyer, J.L.; Lal, S.; Baldessarini, R.J. Historical Highlights of the Chemistry, Pharmacology, and Early Clinical Uses of Apomorphine. In Basic Pharmacology; Gessa, G.L., Corsini, G.U., Eds.; Raven Press: New York, NY, USA, 1981; Volume 1, pp. 1-17.
14. Okun, M.S.; Foote, K.D. Parkinson's disease DBS: What, when, who and why? The time has come to tailor DBS targets. Expert Rev. Neurother. 2010, 10, 1847-1857.
15. Scherkl, R.; Hashem, A.; Frey, H.H. Apomorphine-induced emesis in the dog-routes of administration, efficacy and synergism by naloxone. J. Vet. Pharmacol. Ther. 1990, 13, 154-158.
16. Sydow, O. Parkinson's disease: Recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion. FEBS J. 2008, 275, 1370-1376.
17. Tsuji, A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2005, 2, 54-62.
18. Stefani, A.; Bassi, A.; Mazzone, P.; Pierantozzi, M.; Gattoni, G.; Altibrandi, M.G.; Giacomini, P.; Peppe, A.; Bernardi, G.; Stanzione, P. Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: Lack of clear evidence for the 'indirect pathway'. Clin. Neurophysiol. 2002, 113, 91-100.
19. Merello, M.; Lees, A.J.; Balej, J.; Cammarota, A.; Leiguarda, R. GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine. Mov. Disord. 1999, 14, 481-483.
20. Marsden, C.D.; Parkes, J.D.; Quinn, N. Fluctuations and Disability in Parkinson's Disease: Clinical Aspects. In Movement Disorders; Marsden, C.D., Fahn, S., Eds.; Butterworth Scientific: London, UK, 1982; pp. 96-122.
21. Ahlskog, J.E.; Muenter, M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 2001, 16, 448-458.
22. Carron, R.; Fraix, V.; Maineri, C.; Seigneuret, E.; Piallat, B.; Krack, P.; Pollak, P.; Benabid, A.L.; Chabardès, S. High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: A review. J. Neural. Transm. 2011, 118, 915-924.
23. Antonini, A.; Isaias, I.U.; Rodolfi, G.; Landi, A.; Natuzzi, F.; Siri, C.; Pezzoli, G. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J. Neurol. 2011, 258, 579-585.
24. de Gaspari, D.; Siri, C.; Landi, A.; Cilia, R.; Bonetti, A.; Natuzzi, F.; Morgante, L.; Mariani, C.B.; Sganzerla, E.; Pezzoli, G.; et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J. Neurol. Neurosurg. Psychiatr. 2006, 77, 450-453.
25. Rudzinska, M.; Szczudlik, A. Apomorphine in off state-Clinical experience. Neurol. Neurochir. Pol. 2007, 41, S40-S48.
26. Gancher, S.T.; Nutt, J.G.; Woodward, W.R. Time course of tolerance to apomorphine in parkinsonism. Clin. Pharmacol. Ther. 1992, 52, 504-510.
27. Grandas, F.; Gancher, S.; Lera, G.; Rodriguez, M.; Woodward, W.R.; Nutt, J.; Obeso, J.A. Time interval between repeated injections conditions the duration of motor improvement to apomorphine in Parkinson's disease. Neurology 1992, 42, 1287-1290.
28. Gonzales-Rios, F.; Vlaiculescu, A.; Ben Natan, L.; Protais, P.; Costentin, J. Dissociated effects of apomorphine on various nociceptive responses in mice. J. Neural. Transm. 1986, 67, 87-103.
29. Bonuccelli, U.; Piccini, P.; Del Dotto, P.; Rossi, G.; Corsini, G.U.; Muratorio, A. Naloxone partly counteracts apomorphine side effects. Clin. Neuropharmacol. 1991, 14, 442-449.
30. Poewe, W.; Wenning, G.K. Apomorphine: An underutilized therapy for Parkinson's disease. Mov. Disord. 2000, 15, 789-794.
31. Clarke, C.E.; Worth, P.; Grosset, D.; Stewart, D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15, 728-741.
32. Corsini, G.U.; Del Zompo, M.; Gessa, G.L.; Mangoni, A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet 1979, 1, 954-956.
33. Hughes, A.J.; Kleedorfer, B.B.; Turjanski, N.; Fernandez, W.; Lees, A.J.; Stern, G.M. Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years. Mov. Disord. 1992, 8, 165-170.
34. Deuschl, G.; Schade-Brittinger, C.; Krack, P.; Volkmann, J.; Schafer, H.; Botzel, K.; Daniels, C.; Deutschländer, A.; Dillmann, U.; Eisner, W.; et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 2006, 355, 896-908.
35. NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA 1993, 270, 83-90.
36. Lasker, G.F.; Maley, J.H.; Kadowitz, P.J. A review of the pathophysiology and novel treatments for erectile dysfunction. Adv. Pharmacol. Sci. 2010, doi:10.1155/2010/730861.
37. Fedele, D.; Coscelli, C.; Cucinotta, D.; Forti, G.; Santeusanio, F.; Viaggi, S.; Fiori, G.; Velonà, T.; Lavezzari, M. Incidence of erectile dysfunction in Italian men with diabetes. J. Urol. 2001, 166, 1368-1371.
38. Martin-Morales, A.; Sanchez-Cruz, J.J.; Saenz de Tejada, I.; Rodriguez-Vela, L.; Jimenez-Cruz, J.F.; Burgos-Rodriguez, R. Prevalence and independent risk factors for erectile dysfunction in Spain: Results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J. Urol. 2001, 166, 569-574.
39. Montorsi, P.; Ravagnani, P.M.; Galli, S.; Rotatori, F.; Briganti, A.; Salonia, A. The artery size hypothesis: A macrovascular link between erectile dysfunction and coronary artery disease. Am. J. Cardiol. 2005, 6, 19M-23M.
40. Carson, C.C., III. Erectile dysfunction: Diagnosis and management with newer oral agents. Proc. (Bayl. Univ. Med. Cent.) 2000, 13, 356-360.
41. Shaul, P.W. Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J. Physiol. 2003, 15, 21-33.
42. Stief, C.G. Central mechanisms of erectile dysfunction: What a clinician may want to know. Int. J. Impot. Res. 2003, 15 (Suppl. 2), S3-S6.
43. Gratzke, C.; Angulo, J.; Chitaley, K.; Dai, Y.T.; Kim, N.N.; Paick, J.S.; Simonsen, U.; Uckert, S.; Wespes, E.; Andersson, K.E.; et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J. Sex. Med. 2010, 7, 445-475.
44. Dean, R.C.; Lue, T.F. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol. Clin. N. Am. 2005, 32, 379-395.
45. Heaton, J.P.; Morales, A.; Adams, M.A.; Johnston, B.; el-Rashidy, R. Recovery of erectile function by the oral administration of apomorphine. Urology 1995, 45, 200-206.
46. Von Keitz, A.T.; Ströberg, P.; Bukofzer, S.; Mallard, N.; Hibberd, M. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction. BJU Int. 2002, 89, 409-415.
47. Maclennan, K.M.; Boshier, A.; Wilton, L.V.; Shakir, S.A. Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction. BJU Int. 2006, 98, 125-131.
48. Afif-Abdo, J.; Teloken, C.; Damiao, R.; Koff, W.; Wroclawski, E.; Yamasaki, R.; Torres, L.O.; Sabaneeff, J.; Faria, G.; Pompeo, A.C.; et al. Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. BJU Int. 2008, 102, 829-834.
49. Montorsi, F.; Perani, D.; Anchisi, D.; Salonia, A.; Scifo, P.; Rigiroli, P.; Zanoni, M.; Heaton, J.P.; Rigatti, P.; Fazio, F. Apomorphine-induced brain modulation during sexual stimulation: A new look at central phenomena related to erectile dysfunction. Int. J. Impot. Res. 2003, 15, 203-209.
50. Caruso, S.; Agnello, C.; Intelisano, G.; Farina, M.; Di Mari, L.; Cianci, A. Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder. Urology 2004, 63, 955-959.
51. Sarazin, M.; de Souza, L.C.; Lehéricy, S.; Dubois, B. Clinical and research diagnostic criteria for alzheimer's disease. Neuroimaging Clin. N. Am. 2012, 22, 23-32.
52. Reiman, E.M.; Chen, K.; Liu, X.; Bandy, D.; Yu, M.; Lee, W.; Ayutyanont, N.; Keppler, J.; Reeder, S.A.; Langbaum, J.B.; et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2009, 106, 6820-6825.
53. O'Brien, R.J.; Wong, P.C. Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. 2011, 34, 185-204.
54. Mölsä, P.K.; Marttila, R.J.; Rinne, U.K. Long-term survival and predictors of mortality in Alzheimer's disease and multi-infarct dementia. Acta Neurol. Scand. 1995, 91, 159-164.
55. Mölsä, P.K.; Marttila, R.J.; Rinne, U.K. Survival and cause of death in Alzheimer's disease and multi-infarct dementia. Acta Neurol. Scand. 1986, 74, 103-107.
56. Wimo, A.; Jönsson, L.; Gustavsson, A.; McDaid, D.; Ersek, K.; Georges, J.; Gulácsi, L.; Karpati, K.; Kenigsberg, P.; Valtonen, H. The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int. J. Geriatr. Psychiatry 2011, 26, 825-832.
57. Zahs, K.R.; Ashe, K.H. "Too much good news"-are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci. 2010, 33, 381-389.
58. Jankowsky, J.L.; Slunt, H.H.; Gonzales, V.; Savonenko, A.V.; Wen, J.C.; Jenkins, N.A.; Copeland, N.G.; Younkin, L.H; Lester, H.A.; Younkin, S.G.; et al. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS. Med. 2005, 2, e355.
59. Gandy, S.; Heppner, F.L. Breaking up (amyloid) is hard to do. PLoS. Med. 2005, 2, e417.
60. Gouras, G.K.; Tampellini, D.; Takahashi, R.H.; Capetillo-Zarate, E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol. 2010, 119, 523-541.
61. Lee, J.; Retamal, C.; Cuitino, L.; Caruano-Yzermans, A.; Shin, J.E.; van Kerkhof, P.; Marzolo, M.P.; Bu, G. Adaptor protein sorting nexin 17 regulates amyloid precursor protein trafficking and processing in the early endosomes. J. Biol. Chem. 2008, 283, 11501-11508.
62. Koo, E.H.; Squazzo, S.L. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 1994, 269, 17386-17389.
63. Kinoshita, A.; Fukumoto, H.; Shah, T.; Whelan, C.M.; Irizarry, M.C.; Hyman, B.T. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J. Cell. Sci. 2003, 116, 3339-3346.
64. Fukumori, A.; Okochi, M.; Tagami, S.; Jiang, J.; Itoh, N.; Nakayama, T.; Yanagida, K.; Ishizuka-Katsura, Y.; Morihara, T.; Kamino, K.; et al. Presenilin-dependent gamma-secretase on plasma membrane and endosomes is functionally distinct. Biochemistry 2006, 45, 4907-4914.
65. Parvathy, S.; Hussain, I.; Karran, E.H.; Turner, A.J.; Hooper, N.M. Cleavage of Alzheimer's amyloid precursor protein by alpha-secretase occurs at the surface of neuronal cells. Biochemistry 1999, 38, 9728-9734.
66. Gandy, S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J. Clin. Invest. 2005, 115, 1121-1129.
67. Necula, M.; Kayed, R.; Milton, S.; Glabe, C.G. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 2007, 282, 10311-10324.
68. Padmanabhan, J.; Levy, M.; Dickson, D.W.; Potter, H. Alpha1- antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain 2006, 129, 3020-3034.
69. Mrak, R.E.; Griffin, W.S. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol. Aging 2001; 22, 903-908.
70. Yao, Y.; Chinnici, C.; Tang, H.; Trojanowski, J.Q.; Lee, V.M.; Praticò, D. Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J. Neuroinflamm. 2004, 1, 21.
71. Yang, A.J.; Chandswangbhuvana, D.; Shu, T.; Henschen, A.; Glabe, C.G. Intracellular accumulation of insoluble, newly synthesized abetan-42 in amyloid precursor protein-transfected cells that have been treated with Abeta1-42. J. Biol. Chem. 1999, 274, 20650-20656.
72. Wild-Bode, C.; Yamazaki, T.; Capell, A.; Leimer, U.; Steiner, H.; Ihara, Y.; Haass, C. Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42. J. Biol. Chem. 1997, 272, 16085-16088.
73. LaFerla, F.M.; Green, K.N.; Oddo, S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 8, 499-509.
74. Ohyagi, Y.; Asahara, H.; Chui, D.H.; Tsuruta, Y.; Sakae, N.; Miyoshi, K.; Yamada, T.; Kikuchi, H.; Taniwaki, T.; Murai, H.; et al. Intracellular Ab42 activates p53 promoter: A pathway to neurodegeneration in Alzheimer's disease. FASEB J. 2005, 19, 255-257.
75. Ohyagi, Y. Intracellular amyloid b-protein as a therapeutic target for treating Alzheimer's disease. Curr. Alzheimer Res. 2008, 5, 555-561.
76. Ma, L.; Ohyagi, Y.; Miyoshi, K.; Sakae, N.; Motomura, K.; Taniwaki, T.; Furuya, H.; Takeda, K.; Tabira, T.; Kira, J. Increase in p53 protein levels by presenilin 1 gene mutations and its inhibition by secretase inhibitors. J. Alzheimers Dis. 2009, 16, 565-575.
77. Capetillo-Zarate, E.; Gracia, L.; Yu, F.; Banfelder, J.R.; Lin, M.T.; Tampellini, D.; Gouras, G.K. High-resolution 3D reconstruction reveals intra-synaptic amyloid fibrils. Am. J. Pathol. 2011, 179, 2551-2558.
78. Glabe, C. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J. Mol. Neurosci. 2001, 17, 137-145.
79. Gouras, G.K.; Almeida, C.G.; Takahashi, R.H. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol. Aging 2005, 26, 1235-1244.
80. Meyer-Luehmann, M.; Coomaraswamy, J.; Bolmont, T.; Kaeser, S.; Schaefer, C.; Kilger, E.; Neuenschwander, A.; Abramowski, D.; Frey, P.; Jaton, A.L.; et al. Exogenous induction of cerebral betaamyloidogenesis is governed by agent and host. Science 2006, 313, 1781-1784.
81. Steele, J.W.; Gandy, S. Apomorphine and Alzheimer Aβ: Roles for regulated acleavage, autophagy, and antioxidation? Ann. Neurol. 2011, 69, 221-225.
82. Shin, R.W.; Iwaki, T.; Kitamoto, T.; Tateishi, J. Hydrated autoclave pretreatment enhances tau immunoreactivity in formalin-fixed normal and Alzheimer's disease brain tissues. Lab. Invest. 1991, 64, 693-702.
83. Mawal-Dewan, M.; Henley, J.; van de Voorde, A.; Trojanowski, J.Q.; Lee, V.M. The phosphorylation state of tau in the developing rat brain is regulated by phosphoprotein phosphatases. J. Biol. Chem. 1994, 269, 30981-30987.
84. Taniguchi, T.; Kawamata, T.; Mukai, H.; Hasegawa, H.; Isagawa, T.; Yasuda, M.; Hashimoto, T.; Terashima, A.; Nakai, M.; Mori, H.; et al. Phosphorylation of tau is regulated by PKN. J. Biol. Chem. 2001, 276, 10025-10031.
85. Alonso, A.; Zaidi, T.; Novak, M.; Grundke-Iqbal, I.; Iqbal, K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl. Acad. Sci. USA 2001, 98, 6923-6928.
86. Gouras, G.K.; Tsai, J.; Naslund, J.; Vincent, B.; Edgar, M.; Checler, F.; Greenfield, J.P.; Haroutunian, V.; Buxbaum, J.D.; Xu, H.; et al. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 2000, 156, 15-20.
87. Oddo, S.; Billings, L.; Kesslak, J.P.; Cribbs, D.H.; LaFerla, F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43, 321-332.
88. Milton, V.J.; Sweeney, S.T. Oxidative stress in synapse development and function. Dev. Neurobiol. 2012, 72, 100-110.
89. Gomez-Ramos, A.; Diaz-Nido, J.; Smith, M.A.; Perry, G.; Avila, J. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J. Neurosci. Res. 2003, 71, 863-870.
90. Tamagno, E.; Gugliemotto, M.; Aragno, M.; Borghi, R.; Autelli, R.; Giliberto, L.; Muraca, G.; Danni, O.; Zhu, X.; Smith, M.A.; et al. Oxidative stress activates a positive feedback between the g- and β-secretase cleavages of the β-amyloid precursor protein. J. Neurochem. 2008, 104, 683-695.
91. Su, B.; Wang, X.; Lee, H.G.; Tabaton, M.; Perry, G.; Smith, M.A.; Zhu, X. Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells. Neurosci. Lett. 2010, 468, 267-271.
92. Guglielmotto, M.; Giliberto, L.; Tamagno, E.; Tabaton, M. Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. Front. Aging Neurosci. 2010, 2, doi:10.3389/neuro.24.003.2010.
93. Himeno, E.; Ohyagi, Y.; Ma, L.; Nakamura, N.; Miyoshi, K.; Sakae, N.; Motomura, K.; Soejima, N.; Yamasaki, R.; Hashimoto, T.; et al. Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation. Ann. Neurol. 2011, 69, 248-256.
94. Ma, L.; Ohyagi, Y.; Nakamura, N.; Iinuma, K.M.; Miyoshi, K.; Himeno, E.; Soejima, N.; Yanagihara, Y.T.; Sakae, N.; Yamasaki, R.; et al. Activation of glutathione peroxidase and inhibition of p53-related apoptosis by apomorphine. J. Alzheimers. Dis. 2011, 27, 225-237.
95. Ishige, K.; Chen, Q.; Sagara, Y.; Schubert, D. The activation of dopamine D4 receptors inhibits oxidative stress-induced nerve cell death. J. Neurosci. 2001, 21, 6069-6076.
96. Tampellini, D.; Rahman, N.; Gallo, E.F.; Huang, Z.; Dumont, M.; Capetillo-Zarate, E.; Ma, T.; Zheng, R.; Lu, B.; Nanus, D.M.; et al. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J. Neurosci. 2009, 29, 9704-9713.
97. Huang, X.; Atwood, C.S.; Hartshorn, M.A.; Multhaup, G.; Goldstein, L.E.; Scarpa, R.C.; Cuajungco, M.P.; Gray, D.N.; Lim, J.; Moir, R.D.; et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999, 38, 7609-7616.
98. Hara, H.; Ohta, M.; Adachi, T. Apomorphine protects against 6-hydroxydopamine- induced neuronal cell death through activation of the Nrf2-ARE pathway. J. Neurosci. Res. 2006, 84, 860-866.
99. Boutaud, O.; Ou, J.J.; Chaurand, P.; Caprioli, R.M.; Montine, T.J.; Oates, J.A. Prostaglandin H2 (PGH2) accelerates formation of amyloid beta1-42 oligomers. J. Neurochem. 2002, 82, 1003-1006.
100. Pratico, D.; Sung, S. Lipid peroxidation and oxidative imbalance: Early functional events in Alzheimer's disease. J. Alzheimers Dis. 2004, 6, 171-175.
101. Lashuel, H.A.; Hartley, D.M.; Balakhaneh, D.; Aggarwal, A.; Teichberg, S.; Callaway, D.J. New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J. Biol. Chem. 2002, 277, 42881-42890.
102. Linazasoro, G. The apomorphine test in gait disorders associated with parkinsonism. Clin. Neuropharmacol. 1996, 19, 171-176.